Skip to main content
NewslettersWatchlist

Abcellera Biologics Inc(ABCL-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low3.62
Day High3.88
Open:3.86
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
The Globe and Mail
Short sales on the TSX: What bearish investors are betting against
Motley Fool
AbCellera Biologics (ABCL) Q4 2023 Earnings Call Transcript
Motley Fool
4 Magnificent Healthcare Stocks to Buy in 2024 and Beyond
Motley Fool
3 Growth Stocks That Could Go Parabolic in 2024
The Globe and Mail
AbCellera cuts 10 per cent of staff as biotech slump hits Vancouver antibody developer
SYNDTGAM
Cutting-edge antibody therapy firm AbCellera to lay off 10% of work force
Motley Fool
AbCellera Biologics (ABCL) Q3 2023 Earnings Call Transcript
MarketBeat
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Motley Fool
AbCellera Biologics (ABCL) Q2 2023 Earnings Call Transcript
Motley Fool
AbCellera Biologics (ABCL) Q1 2023 Earnings Call Transcript
Business Wire
AbCellera Reports Q1 2023 Business Results
Motley Fool
How AI Is Revolutionizing Tech, and Why You Should Invest in These Leading Companies
The Globe and Mail
AbCellera-backed precision medicine startup Abdera raises $140-million to target tumors
Business Wire
AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023
Motley Fool
1 Sector Received $6.1 Billion in AI Investments Last Year: 3 Top Stocks to Buy
Business Wire
AbCellera to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023
Business Wire
AbCellera to Report First Quarter 2023 Financial Results on May 4, 2023
Business Wire
AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease
Business Wire
AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023
The Globe and Mail
Tuesday’s analyst upgrades and downgrades
Business Wire
AbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023
Motley Fool
AbCellera Biologics (ABCL) Q4 2022 Earnings Call Transcript
Business Wire
AbCellera Reports Full Year 2022 Business Results
Business Wire
AbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023
Business Wire
AbCellera to Report Full Year 2022 Financial Results on February 21, 2023
Business Wire
AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent
The Globe and Mail
Friday’s analyst upgrades and downgrades
Business Wire
AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023
Business Wire
AbCellera and AbbVie Partner to Advance New Antibody Therapies
Barchart
Pre-Market Brief: Stocks Plunge On Hawkish Fed Signals, ECB Decision In Focus
Business Wire
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases
Business Wire
AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022

Profile

AbCellera Biologics Inc. is a technology company which searches, decodes and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera Biologics Inc. is based in Vancouver, Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.